The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients

Transplantation

Volumn 69, Issue 9, 2000, Pages 1867-1872

  Eckhoff, Devin E ^a,b   McGuire, Brendan ^a   Sellers, Marty ^a   Contreras, Juan ^a   Frenette, Luc ^a   Young, Carlton ^a   Hudson, Sharon ^a   Bynon, J Stevenson ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; CYCLOSPORIN A; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS;

ADULT; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0034658102     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200005150-00022     Document Type: Article

References (25)

1. Rimola A, Gavaler JS, Schade RR, El-Lankany S, Starzl TE, Van Thiel DH. Effects of renal impairment on liver transplantation. Gastroenterology 1987; 93(1): 148.
2. Brown R Jr, Lombardero Lake J. Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. Transplantation 1996: 62: 1788.
3. Gonwa TA, Klintmalm GB, Levy M, Jennings LS, Goldstein R, Husberg BS. Impact of pretransplant renal function on survival after liver transplantation. Transplantation 1995; 59(3); 361.
4. Platz K, Mueller A, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation: a comparison between cyclosporin and FK506. Transplantation 1994: 58: 170.
5. Baliga P, Merion RM, Turcote JG, et al. Preoperative risk factor assessment in liver transplantation. Surgery 1992: 112(4): 704.
6. Cuervas-Mons V, Millan I, Gavaler JS, Starzl TE, Van Thiel DH. Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology 1986; 6(5): 992.
7. Eckhoff DE, Pirsh JD, D'Alessandro AM, et al. Pretransplant status and patient survival following liver transplantation. Transplantation 1995; 60: 920.
8. Porayko M, Textor S, Krom R, et al. Nephrotoxic effects of primary immunosuppression with FK506 and cyclosporin regimens after liver transplantation. Mayo Clinic Proc 1994: 69: 105.
9. Eckhoff D, McGuire B, Frenette L, Contreras J, et al. tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998: 65: 180.
10. Present D, Korelitz B, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6 mercaptopurine. N Engl J Med 1980; 302: 981.
11. Korelitz B, Present D. Shortcomings of the national Crohn's disease study: the exclusion of azathioprine without adequate trial. Gastroenterology 1981; 80: 193.
12. Smith KA. Interleukin-2: inception, impact and implications. Science 1988; 240: 1169.
13. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245.
14. Amlot PO, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (VD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748.
15. Nashan B, Moore R, Amlot P, Schmidt A-G, Abeywickrama K, Soulillou J-P. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350: 1993.
16. Vincenti F, Kirkman R, Light S, et al.: Interleukin-2-receptor blockage with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 1998; 338: 161.
17. Nashan B, Light S, Hardie I, et al. Reduction of acute renal allograft rejection by daclizumab. Transplantation 1999; 67: 110.
18. Brems J, Hiatt J, Colonna J, et al. Variables influencing the outcome following orthotopic liver transplantation. Arch Surg 1987; 122: 1109.
19. Gayowski T, Marino I, Singh N, et al. Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity. Transplantation 1998; 65: 499.
20. Grande L, Rimola A, Cugat E, et al. Effect of venovenous bypass on perioperative renal function in liver transplantation: results of a randomized, controlled trial. Hepatology 1996; 23: 6: 1418.
21. Bismuth H, Castaing D, Sherlock D. Liver transplantation by face-a-face venacavaplasty. Surgery 1992; 111: 151.
22. Fung J, Starzl T. Prophylactic use of OKT3 in liver transplantation: a review. Dig Dis Sci 1991; 36: 1427.
23. Wiesner RH, Demetris J, Belle SH, et. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology 1998; 28(3): 638.
24. Doyle HR, Marino IR, Morelli F, et al. Assessing risk in liver transplantation. Ann Surg 1996; 224(2): 168.
25. Hathaway M, Gunson BK, Keogh AC, Briggs D, McMaster P, Neuberger JM. A positive crossmatch in liver transplantation: no effect or inappropriate analysis? Transplantation 1997; 64(1): 54.